Zdrowie i gospodarka · 01/06/2015

FDA to Host Public Meeting on Patient-Focused Drug Development for Alpha-1 Antitrypsin Deficiency

The FDA is hosting a public meeting to gather patients' perspectives on the impact of Alpha-1 Antitrypsin Deficiency on daily life and the available therapies for this disorder, as part of its Patient-Focused Drug Development initiative under the Prescription Drug User Fee Act (PDUFA V).